Claims for Patent: 7,977,317

Summary for Patent: 7,977,317

Title:	Compositions and methods for modulating blood-brain barrier transport
Abstract:	This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.
Inventor(s):	Beliveau; Richard (Ile Des Soeurs, CA), Demeule; Michel (Longueuil, CA), Yang; Joseph (North Delta, CA), Kennard; Malcolm L. (North Vancouver, CA), Gabathuler; Reinhard (San Rafael, CA)
Assignee:	Raptor Pharmaceutical Inc. (Novato, CA)
Application Number:	12/683,651
Patent Claims:	1. A method of delivering an active agent across the blood brain barrier in a subject in need thereof comprising administering a composition comprising a conjugate comprising receptor associated protein (RAP) and an active agent. 2. The method of claim 1 wherein the composition further comprises a pharmaceutically acceptable carrier. 3. The method of claim 1 wherein the active agent is a protein. 4. The method of claim 1 wherein the subject is suffering from a neurological cancer selected from the group consisting of a primary brain tumor, glioblastoma, glioma, meningioma, neurinoma, pituitary adenoma, medulloblastoma, craniopharyngioma, hemangioma, epidermoid, sarcoma and intracranial metastasis from other tumor sources. 5. The method of claim 1 wherein the active agent is a chemotherapeutic agent. 6. The method of claim 5 wherein the chemotherapeutic agent is selected from the group consisting of an alkylating agent, an alkaloid, an anti-metabolite, an antibiotic, and an anti-proliferative agent. 7. The method of claim 5 wherein the chemotherapeutic agent is selected from the group consisting of Mechlorethamine hydrochloride, Cyclophosphamide, Ifosfamide, Chlorambucil, Melphalan, Busulfan, Thiotepa (Triethylenethiophosphoramide), Carmustine, Lomustine, Streptozocin, Vincristine, Vinblastine, Paclitaxel, Methotrexate, Mercaptopurine, Thioguanine, Fluorouracil, Cytarabine, Azacitidine, Dactinomycin, Doxorubicin, Daunorubicin, Idarubicin, Bleomycin, Picamycin, Mitomycin, Hydroxyurea, Procarbazine, Dacarbazine, Cisplatin, Carboplatin, Asparaginase, Etoposide, Amsarcrine, Mitotane, and Mitoxantrone. 8. The method of claim 1 wherein the subject is suffering from a neurological disease selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, schizophrenia and epilepsy. 9. The method of claim 1 wherein the active agent is for treating a neurological disorder.

Details for Patent 7,977,317

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2021-07-25